XOMA (NASDAQ:XOMA - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.
Separately, HC Wainwright reiterated a "buy" rating and set a $104.00 price target on shares of XOMA in a research note on Wednesday, March 19th.
Read Our Latest Analysis on XOMA
XOMA Stock Down 0.9 %
Shares of NASDAQ:XOMA traded down $0.19 on Friday, hitting $20.74. 29,881 shares of the company's stock were exchanged, compared to its average volume of 26,554. XOMA has a 1-year low of $19.92 and a 1-year high of $35.00. The company has a market capitalization of $248.44 million, a PE ratio of -5.96 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The firm's 50-day moving average is $24.16 and its 200 day moving average is $27.03.
XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.75 million. Sell-side analysts predict that XOMA will post -1.41 EPS for the current year.
Insider Buying and Selling
In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CIO Bradley Sitko purchased 4,134 shares of the company's stock in a transaction that occurred on Friday, March 21st. The stock was bought at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the transaction, the executive now directly owns 10,484 shares in the company, valued at $250,462.76. This trade represents a 65.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 4,747 shares of company stock worth $114,544 in the last quarter. 7.20% of the stock is owned by insiders.
Institutional Trading of XOMA
A number of hedge funds have recently added to or reduced their stakes in XOMA. BNP Paribas Financial Markets increased its holdings in shares of XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares during the period. New York State Common Retirement Fund increased its stake in XOMA by 51.2% in the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after buying an additional 800 shares during the period. Wells Fargo & Company MN increased its stake in XOMA by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after buying an additional 1,183 shares during the period. Bank of America Corp DE raised its position in XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after buying an additional 2,009 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of XOMA in the 4th quarter worth $206,000. 95.92% of the stock is owned by institutional investors and hedge funds.
XOMA Company Profile
(
Get Free Report)
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
Featured Articles
Before you consider XOMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XOMA wasn't on the list.
While XOMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
